Haemocoagulation and renal insufficiency, haemocoagulation and type 2 diabetes mellitus

Czech version

Authors: J. Malý; M. Šimkovič; M. Pecka
Authors‘ workplace: II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
Published in: Vnitř Lék 2008; 54(5): 452-456
Category:

Overview

Diabetes mellitus is a frequent cause of renal insufficiency. Renal insufficiency is associated with both haemorrhagic manifestations primarily caused by platelet functional disorders, and states of hypercoagulation resulting from significant hyperfibrinogenemia. Fibrinolysis is either increased or, often, decreased. Changes in haemostasis in renal insufficiency have been dealt with by many authors in relevant literature. However, the final stage of renal insufficiency is rather dominated by haemorrhagic diathesis. It is manifested by skin haemorrhage, mucosal manifestations, but also by retroperitoneal and cerebral haemorrhage. The main cause of a haemorrhagic condition is platelet dysfunction combined with anticoagulation and antiplatelet therapy which is used in dialysis. Platelet function disorders are provoked by acquired thrombocytopaenia and result in a disorder in the interaction between the blood vessel wall and the platelet. Dialysis suppresses platelet abnormalities only temporarily by suppressing uremic toxins provoking platelet disorders. On the other hand, dialysis may cause prothrombotic activity. Changes in haemostasis in type 2 diabetes mellitus form part of the insulin resistance syndrome and induce prothrombotic condition due to decreased fibrinolysis.

Key words:
haemocoagulation – renal insufficiency – diabetes mellitus

Sources

1. Morgagni GB. Opera Omnia Ex Typographia Remondiniana. Venezia 1764.

2. Bright R. Tabular view of morbid appearance in 100 cases connected with albuminous urine: with observations. Guy's Hosp Rep 1836; 1: 380-400.

3. Rabiner SF, Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 1970; 49: 346-351.

4. Horowitz HI, Stein IM, Cohen BD et al. Further studies on platelet inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 1970; 49: 336-345.

5. Rabiner SF, Hrodek O. Platelet factor 3 in normal subjects and patients with renal failure. J Clin Invest 1968; 47: 901-912.

6. Malý J, Jebavý L, Široký O et al. Poruchy hemostázy při ledvinové nedostatečnosti. Sbor. věd. prací VLVDÚ JEP Hradec Králové 1981; 86: 171-219.

7. Malý J, Erben J, Pecka M et al. Změny agregace destiček u nemocných v chronickém intermitentním dialyzačním programu. Sbor. věd. prací LF UK Hradec Králové 1982; 25: 295-306.

8. Malý J, Pecka M, Erben J et al. Fibrin degradační produkty (FDP) v moči po transplantaci ledvin. Vnitř Lék 1983; 29: 598-603.

9. Malý J, Kačerovský J, Pecka M et al. Sledování změn hemostázy u nemocných s vleklou ledvinovou nedostatečností léčených peritoneální dialýzou. Sbor. věd. prací LF UK Hradec Králové 1982; 25: 277-293.

10. Pecka M. Laboratorní hematologie v přehledu. Fyziologie a patofyziologie hemostázy. Český Těšín: FINIDR 2004.

11. Kottke-Marchant K, Corcoran G. The Laboratory Diagnosis of Platelet Disorders. Arch Pathol Lab Med 2001; 126: 133-146.

12. Malý J. Vyšetření aktivity destičkových funkcí se vztahem k resistenci na kyselinu acetylsalicylovou Vnitř Lék 2005; 51: 157-162.

13. Sloand EM, Sloand JA, Prodouz K. Reduction of platelet glycoprotein Ib in uremia. Br J Haematol 1991; 77: 375-381

14. Benigni A, Boccardo P, Galbusera M. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993; 22: 668-676.

15. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIa-IIIb receptors. Am J Kidney Dis 1996; 27: 355-364.

16. Viachoyannia J, Schoeppe W. Adenylyl cyclase activity and cyclic AMP content of human platelets in uremia. Eur J Clin Invest 1982; 12: 379-381.

17. Moncada S, Herman AG, Higgs EA et al: Differential formation of prostacyclin (PGI2) by layers of arterial wall: an explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977; 11: 323-344.

18. Livio M, Benigni A, Vigano G et al. Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1986; 1: 414-416.

19. Marietta M, Facchinetti F, Neri I. L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. Thromb Res 1997; 88: 229-235.

20. Remuzzi G, Benigni A, Dodesini P et al. Parathyroid hormone inhibits human platelet function. Lancet 1981; 2: 1321-1323.

21. Fernandez F, Goudable C, Sie P. Low hematocrit and prolonged bleeding time in uremic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139-148.

22. Moia M, Mannucci PM, Vizzotto L. Improvement in the haemostatic defect of uremia after treatment with recombinant human erythropoietin. Lancet 1987; 2: 1227-1229.

23. Cases A, Escolar G, Reverter JC et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992; 42: 668-672.

24. Andrassy K, Ritz E. Uremia as a cause of bleeding. Am J Nephrol 1985; 5: 313-319.

25. Bang N, Tessler S, Heidenreich R et al. Effects of moxolactam on blood coagulation and platelet function. Rev Infect Dis 1982; 4: S546-S554.

26. Harker LA, Fuster V. Pharmacology of platelet inhibitors. J Am Coll Cardiol 1986; 8: 21B-32B.

27. Ando M, Iwata A, Ozeki Y et al. Circulating platelet derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002; 62: 1757-1763.

28. Bonomini M, Dottori S, Amoroso L et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004; 2: 1275-1281.

29. Juhan-Vague I, Morange P, Renucci JF et al. Fibrinogen, obesity and insulin resistance. Blood Coagul Fibrinolysis 1999; 10(Suppl 1): S25-28.

30. Kvasnička J, Škrha J. Increase in tissue plasminogen activator (t-PA) in relation to microangiopathy in type I diabetes mellitus. Cor Vasa 1994; 36: 280-285.

31. Škrha J, Hodinář A, Kvasnička J et al. Relationship of Oxidative Stress and Fibrinolysis in Diabetes Mellitus. Diabet Med 1996; 13: 800-805.

32. Ranieri R et al. Mean platelet volume in obesity its relation to visceral fat and to cardiovascular risk factor. Int J Obesity 1996; 20(Suppl 4): 115.

33. De Pergola G, De Mitrio V, Sciaraffia M et al. Haemostatic factors in non diabetic premenopausal obese women. Int J Obesity 1996; 20(Suppl 4): 1135.

34. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207.

35. De Lorenzo F, Mukherjee M, Karziola Z et al. Association of Overal Adiposity rather than Body Mass Indes with Lipids and Procoagulant Factors. Thromb Haemost 1998; 80: 603-606.

36. De Pergola G, Pannacciulli N, Minenna A et al. Fuel metabolism in adult individuals with a wide range of body mass index: effect of a family history of type 2 diabetes. Diabetes Nutr Metab 2003; 16: 41-47.

37. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci 1998; 95: 7591-7596.

38. Sakamoto T, Woodcock-Mitchell J et al. TNF-α and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am J Physiol 1999; 276: 1391-1397.

39. Morange PE, Alessi MC, Juhan-Vague I. Relations between hemostatic variables, insulin resistance and inflammation. Hematol J 2004; 5(Suppl 3): S15-S19.

40. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999; 22(Suppl 3): 25-30.